|
An
Interesting Career in Psychology:
Clinical
Neuropsychopharmacologist
Richard
J. Katz, PhD, Novartis Pharmaceuticals Corporation
There
is a certain clueless quality to many a graduate
student's post-matriculation planning. When I
graduated from Bryn Mawr College with a PhD in
psychology and a comparative and physiological
specialization, I had two postdoctoral
opportunities: one in central nervous system
(CNS) regional neurochemistry and the other in
the clinical biology of depression. I went for
the latter, spending 4 years at the Mental Health
Research Institute at the University of Michigan
working with Barney Carroll. Nothing I had
experienced previously provided the heuristic
immediacy and salience of close clinical
observation, either for phenomenology or the
biology of the therapeutic response.
My
first real (i.e., postdoctoral) job was a
standard academic appointment. Several factors
obliged my questioning this as a personal best
fit--the two most compelling being the difficulty
in obtaining stable and secure extramural funding
and the relative "distance" of the
classroom from the clinic. I moved to Ciba-Geigy
Pharmaceuticals as a clinical trials monitor to
remedy both. I've been with Ciba (now Novartis
due to a merger) since, but have assumed a bit
more managerial responsibility over time.
Trials
monitors have advanced degrees (MD, PhD, PharmD,
or DO) in a variety of disciplines. Typically,
they have substantive grounding in their field of
inquiry, with solid, broad, and reasonably
general critical and methodological skills.
Beyond that there is rather remarkable latitude
in background--my department includes two
psychologists, two pharmacologists, a physical
anthropologist, an osteopathic physician, and a
neurologist. The job is varied, but typically
embodies aspects of management and oversight.
Monitors write protocols for the conduct of
clinical trials, identify investigators, ensure
patient safety and adherence to good clinical
practices during trial conduct, examine data for
trends, and write clinical reports and reviews
for internal and regulatory purposes. For
successful drugs (a good batting average in CNS
is anything over .100), monitors further
integrate clinical data into rather massive
requests to the Food and Drug Administration for
regulatory approval. Therefore, being able to
write rapidly and accurately is essential.
The
responsibilities in a CNS unit are diverse. Over
the years, I have worked on drugs for Alzheimer's
disease, multi-infarct dementia, depression,
anxiety, obsessive-compulsive disorder,
posttraumatic stress disorder, social phobia,
epilepsy, and jet lag. In our current debates on
prescribing privileges for psychologists, it
should be recognized that psychologist-monitors
have been instrumental in establishing the safety
and efficacy of many of the drugs in question:
clomipramine for obsessive- compulsive disorder
(a personal success), tacrine for Alzheimer's
disease, buspirone for anxiety, and nimodipine
for subarachnoid hemorrhage. One of the pluses of
the job is the chance to do fully funded clinical
work with large (occasionally upward of 1,000)
patient populations. Typically, we are looking to
treat conditions for which therapies are not
established or are fundamentally inadequate, so
there is the opportunity to engage in innovative
clinical science. Moreover, when something
happens, it matters--to see patients who have
been disabled for most of their adult lives
improve and re-engage, even if only on paper case
records, is gratifying, and when your drug is
approved, you can simultaneously change medical
practice and benefit millions of lives. The range
of conditions on the job demands a willingness to
learn a new subdiscipline every few years, and
this continual learning is stimulating. Other
advantages of the job include good extramural
collaboration with investigators and occasional
international travel. The pay and benefits are
also better than for parallel academic positions.
The
major negatives actually are related to the
pluses. Although there is great latitude in
underlying diseases treated, there must be a
willingness to work on assigned projects. Thus,
there is far less choice of intellectual focus.
Travel can vary and can occasionally reach 50% of
one's time. This is rare, but can be personally
and physically demanding. I'm not certain whether
this is a positive, a negative, or a neutral, but
publication is a low priority. Some of us
continue to publish a paper or two per year, but
there is no material consequence. Your job goes
on with or without it. Papers may be held to
ensure maximizing patent protections, but this
probably is no longer unique to industry.
There
is no single way to become a clinical trials
monitor. If I were looking to prepare myself, I
certainly would focus my doctoral or postdoctoral
work on clinical problems, possibly doing
psychiatric research. There are a large number of
drug firms in the Boston-New
York-Philadelphia-Wilmington corridor, and they
support upward of 100 search firms that place
candidates. The New York Sunday Times
"Help Wanted" section has an extensive
listing under "pharmaceuticals." In
addition to pharmaceutical firms, head hunters
are also advertised. And finally, networking
should not be underestimated as a way to break
into the field. •
(Originally published in the July/August 1997 issue of Psychological
Science Agenda, the newsletter of the APA Science Directorate.)
More Interesting
Careers in Psychology....
|